Table 2: In vitro antifungal susceptibility (fungicidal ~MIC100) of <em>Candida auris</em> and Candida glabrata to Amphotericin-B (AmB) deoxycholate, and liposomal preparations of Amphotericin-B.

Table 2: In vitro antifungal susceptibility (fungicidal ~MIC100) of Candida auris and Candida glabrata to Amphotericin-B (AmB) deoxycholate, and liposomal preparations of Amphotericin-B.

Origin	Candida strains	AmB-deoxycholate	Liposomal AmB
Origin	Candida strains	Amfocare™	AmBisome®	FUNGISOME®,
Japan	C. auris CDC 0381	0.25	2	0.125
South Asia	C. auris CDC 0382	0.21	2	0.25
South Africa	C. auris CDC 0383	0.5	4	0.5
South Africa	C. auris CDC 0384	0.5	8	0.5
Venezuala	C. auris CDC 0385	1	16	0.5
Venezuala	C. auris CDC 0386	32	> 32	0.83
Pakistan	C. auris CDC 0387	32	32	0.25
Pakistan	C. auris CDC 0388	0.33	> 32	1
South Asia	C. auris CDC 0389	1	> 32	1.33
South Asia	C. auris CDC 0390	0.5	> 32	0.83
N/A	C. glabrata CDC 0317	0.25	1	0.125
GM^#		0.53 ± 0.31 (n = 8)	6.4 ± 5.9 (n = 5)	0.6 ± 0.4 (n = 10)
MIC50		0.25-0.5		0.125-0.25
MIC90		32	32	1.3
^**CLSI-50		0.5	N/A
^**CLSI-90		2	N/A

N/A: Not available: ^**CLSI method-based tentative cutoff breakpoint of susceptibility for C. auris as reported by Arendrup, et al. 2017. ^#Geometric mean ± S.D., the Values of resistant strains (gray cell ≥ 32) are not included.